Literature DB >> 576843

Long-term treatment of acromegaly with bromocriptine.

J A Wass, M O Thorner, D V Morris, L H Rees, A S Mason, A E Jones, G M Besser.   

Abstract

Seventy-three patients with active acromegaly were treated for three to 25 months with bromocriptine 10-60 mg/day. Seventy-one patients showed symptomatic and objective clinical improvement. This included reduction in excessive sweating, hand and foot size, and the number of headaches; improved facial appearance; and increased energy and libido. Abnormal visual fields became normal in two patients, one of whom had concomitant radiotherapy. Mean circulating growth hormone levels, obtained by averaging serial samples through the day, fell by more than 7 microng/l or became undetectable in 58 patients (79%) but did not reach normal values: only 15 patients had mean levels on treatment of 5 microng/l or less. Twenty-three patients were diabetic before treatment, and glucose tolerance became normal in 15 and improved in a further five. Provided the drug was started slowly side effects were minor when compared with the considerable clinical benefit obtained.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 576843      PMCID: PMC1605996          DOI: 10.1136/bmj.1.6065.875

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  Suppression of pituitary tumor growth and function by ergot alkaloids.

Authors:  R M MacLeod; J E Lehmeyer
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

2.  Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration.

Authors:  A Liuzzi; P G Chiodini; L Botalla; G Cremascoli; E E Müller; F Silvestrini
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

3.  Gastrointestinal bleeding in patients on bromocriptine.

Authors:  E del Pozo; W P Maclay
Journal:  Lancet       Date:  1976-10-23       Impact factor: 79.321

4.  Gastrointestinal bleeding in patients on bromocriptine.

Authors:  J A Wass; M O Thorner; G M Besser; D Morris; A S Mason; A Liuzzi; P G Chiodini
Journal:  Lancet       Date:  1976-10-16       Impact factor: 79.321

5.  Radioimmunoassay of human prolactin.

Authors:  A S McNeilly
Journal:  Proc R Soc Med       Date:  1973-09

6.  Letter: Digital vasospasm with bromocriptine.

Authors:  J A Wass; M O Thorner; G M Besser
Journal:  Lancet       Date:  1976-05-22       Impact factor: 79.321

7.  Bromocriptine treatment of acromegaly.

Authors:  M O Thorner; A Chait; M Aitken; G Benker; S R Bloom; C H Mortimer; P Sanders; A S Mason; G M Besser
Journal:  Br Med J       Date:  1975-02-08

8.  Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.

Authors:  F Camanni; F Massara; L Belforte; G M Molinatti
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

9.  Bromocriptine therapy in acromegaly.

Authors:  Y Sachdev; A Gomez-Pan; W M Tunbridge; A Duns; D R Weightman; R Hall; S K Goolamali
Journal:  Lancet       Date:  1975-12-13       Impact factor: 79.321

10.  Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses.

Authors:  A Liuzzi; P G Chiodini; L Botalla; F Silvestrini; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

View more
  33 in total

Review 1.  A history of acromegaly.

Authors:  R Sheaves
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  Treatment of pituitary tumors: history.

Authors:  Gaya Thanabalasingham; Niki Karavitaki; Simon Cudlip; John A H Wass
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

3.  Rapid progression of a growth hormone producing tumour during dopamine agonist treatment.

Authors:  K Heidvall; A L Hulting
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-28

Review 4.  Bromocriptine in the treatment of acromegaly.

Authors:  D E Bateman; W M Tunbridge
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

Review 5.  Prolactin: role in health and disease.

Authors:  D F Horrobin
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

6.  Rapid enlargement of non-functioning pituitary tumour following withdrawal of bromocriptine.

Authors:  J D Clark; T Wheatley; O M Edwards
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-03       Impact factor: 10.154

7.  Hyperhidrosis in acromegaly: effectiveness of topical aluminium chloride hexahydrate solution.

Authors:  I A MacFarlane; D Knass; C G Beardwell; S M Shalet
Journal:  Br Med J       Date:  1979-10-13

8.  Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine.

Authors:  M T Hyyppä; V A Långvik; U K Rinne
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 9.  Acromegaly update--etiology, diagnosis and management.

Authors:  S Melmed; J A Fagin
Journal:  West J Med       Date:  1987-03

10.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.